Singapore markets open in 35 minutes

Neumora Therapeutics, Inc. (NMRA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.69+0.02 (+0.21%)
At close: 04:00PM EDT
9.69 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.67
Open9.70
Bid9.67 x 300
Ask9.73 x 100
Day's range9.29 - 9.74
52-week range8.82 - 21.00
Volume324,407
Avg. volume629,156
Market cap1.546B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.59
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est25.25
  • GlobeNewswire

    Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

    Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study Navacaprant is also currently in Phase 3 development for the treatment of MDD with data from KOASTAL-1 anticipated in the fourth quarter of 2024 WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pip

  • GlobeNewswire

    Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

    On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of 2024, including Phase 2 study in bipolar depression with navacaprant and Phase 1b study in Alzheimer's disease agitation with NMRA-511 Strong financial position with $423.0 million in cash, cash equivalents and marketable securities expected to support operations into 2026, providing runway through multi

  • GlobeNewswire

    Neumora Therapeutics to Participate in Upcoming Conferences in May

    WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in May: BofA Securities Healthcare Conference 2024: Members of management will participate in a fireside chat on Tuesday, May 14, 2024, at 1:00 PM ET (10:00 AM PT) in Las Vegas, NV.2024